Evidence map›Paper›PMID 35869757›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2022

[VIPR1 promoter methylation promotes transcription factor AP-2

S Ning, C He, Z Guo, H Zhang, Z Mo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

S NingSchool of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin 541199, China.
C HeFaculty of Basic Medical Sciences, Guilin Medical University, Guilin 541199, China.
Z GuoSchool of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin 541199, China.
H ZhangSchool of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin 541199, China.
Z MoSchool of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin 541199, China.
Guilin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the transcriptional regulation mechanism and biological function of low expression of vasoactive intestinal peptide receptor 1 (VIPR1) in hepatocellular carcinoma (HCC).

methodsWe constructed plasmids carrying wild-type VIPR1 promoter or two mutant VIPR1 promoter sequences for transfection of the HCC cell lines Hep3B and Huh7, and examined the effect of AP-2

resultsCompared with the wild-type VIPR1 promoter group, co-transfection with the vector carrying two promoter mutations and the AP-2

conclusionVIPR1 promoter methylation in HCC promotes the binding of AP-2

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansLuciferasesMethylationMiceMice, NudeReceptors, Vasoactive Intestinal Polypeptide, Type ITranscription Factor AP-2LuciferasesReceptors, Vasoactive Intestinal Polypeptide, Type ITranscription Factor AP-2VIPR1 protein, humanhepatocellular carcinomamethylationtranscription factor AP-2αtumor growthvasoactive intestinal peptide receptor 1

Identifiers

PMID35869757
PMCPMC9308875
OpenAlexW4286818422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.